Alkermes and Jazz: Two Different Approaches to Neuroscience, Oncology Portfolios

Dublin-based Alkermes is one of the industry’s most recent examples of a global biopharma spinning off a business as part of its strategy to generate profitability and cash flow. Alkermes entered 2024 as a pure-play neuroscience company focused on difficult-to-treat psychiatric and neurological disorders, having completed the separation of its oncology business into a new company, Mural Oncology, in November 2023.